Loading
Annovis Bio, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 21 May 2026.
Annovis Bio, Inc.: what insiders have been doing
This page follows insider dealings at Annovis Bio, Inc. as filed with SEC (Form 4), a company from the Healthcare & Pharma sector. The last twelve months, up to 18 October 2026, brought 14 filings signed by 3 insiders.
Not one open-market sale was filed. On the buying side, 2 insiders reported 13 purchases totalling €3.6M. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Among those who bought: 1 senior executive and 1 chief executive. Hoffman Michael B filed the largest purchase, €1.7M, on 12 November 2025.
In the case of 8 purchases, another manager of the company was buying within the same 30 days. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase. The most recent open-market purchase was published on 21 May 2026, 149 days ago. Filings reach the SEC (Form 4) feed a median of 1 day after the trade. The legal deadline for a Form 4 is two business days after the transaction.
For context, the typical company on the same exchange (median of 5,816 companies) published 19 filings over the same period, against 14 filings here. Our records for Annovis Bio, Inc. go back to 2021, with 17 purchases and no sales on the open market in total.
In the same sector, recent insider purchases at Cooper Companies, Inc. and Anixa Biosciences Inc also feature in our signals. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
48
Thresholds
n/a
Buy Volume
€4M
17 ops. · all time
Sell Volume
n/a
n/a
Who traded when
BuySaleMichael B. Hoffman13 buys
Maria-Luisa Maccecchini1 buy
Since the insiders bought
- -52.9%Entry US$2.23 · Close 15 Oct 2026 US$1.05
- +3.5%Entry US$2.29 · Close at T+90 US$2.37
- -59.4%Entry US$30.81 · Close at T+365 US$12.50
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Annovis Bio, Inc. Strong Buy (bullish), based on 3 analysts. Average price target: US$11.00.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$1.72
Analyst consensus
3 analystsStrong buy
US$8.00Target US$11.00(+540%)US$17.00
Income statement
EBITDA-US$29.7M
Net income-US$28.9M0.0% margin
Valuation
PER (forward)-1.9x
P/Book16.8x
Beta1.24
Balance sheet & cash
Market capUS$73.3M
Free Cash Flow-US$25.6M
Profitability & ownership
ROE-703.7%
ROA-142.4%
% insiders6.7%
% institutions27.9%
Last declaration on 21 May 2026
Declarations48 total
18,849 shares@ US$1.800.046% mcap0.5% of flowCommon StockSEC:0001104659-26-065311:1
Canonical exit: 18 Aug 2026 (T+90)
54,933 shares@ US$1.89990.14% mcap1.5% of flowCommon StockSEC:0001104659-26-065311:2
Canonical exit: 18 Aug 2026 (T+90)
2,562 shares@ US$1.750.0061% mcap0.1% of flowCommon StockSEC:0001104659-26-065311:0
Canonical exit: 18 Aug 2026 (T+90)
713,800 shares@ US$2.1021.0% of flowCommon StockSEC:0001104659-26-039675:0
Canonical exit: 1 Jul 2026 (T+90)
30,000 shares@ US$4.33981.8% of flowCommon StockSEC:0001104659-25-119407:0
Canonical exit: 8 Mar 2026 (T+90)
1,489 shares@ US$4.130.1% of flowCommon StockSEC:0001104659-25-115801:0
Canonical exit: 22 Feb 2026 (T+90)
9,200 shares@ US$3.850.5% of flowCommon StockSEC:0001104659-25-115801:1
Canonical exit: 22 Feb 2026 (T+90)
415 shares@ US$4.140.0% of flowCommon StockSEC:0001104659-25-115801:2
Canonical exit: 22 Feb 2026 (T+90)
28,096 shares@ US$4.151.6% of flowCommon StockSEC:0001104659-25-115801:3
Canonical exit: 22 Feb 2026 (T+90)
10,000 shares@ US$3.490.5% of flowCommon StockSEC:0001104659-25-115090:0
Canonical exit: 19 Feb 2026 (T+90)
15,000 shares@ US$2.110.4% of flowCommon StockSEC:0001104659-25-113459:0
Canonical exit: 12 Feb 2026 (T+90)
97,561 shares@ US$2.0511.9% of flowCommon StockSEC:0001104659-25-109906:0
Canonical exit: 26 Jan 2026 (T+90)
975,610 shares@ US$2.0527.8% of flowCommon StockSEC:0001104659-25-109905:0
Canonical exit: 26 Jan 2026 (T+90)
7,142 shares@ US$0.145.2% of flowCommon StockSEC:0001104659-25-109904:0
5,000 shares@ US$2.280.2% of flowCommon StockSEC:0001104659-25-087077:0
6,717 shares@ US$2.600.2% of flowCommon StockSEC:0001104659-25-080981:0
500 shares@ US$2.90100.0% of flowCommon StockSEC:0001104659-25-060632:0
25,000 shares@ US$2.801.0% of flowCommon StockSEC:0001104659-25-059897:0
2,000 shares@ US$2.9516.5% of flowCommon StockSEC:0001104659-25-058521:0
46,000 shares@ US$3.379.4% of flowCommon StockSEC:0001104659-25-056578:0
5,000 shares@ US$2.430.2% of flowCommon StockSEC:0001104659-25-055487:0
10,000 shares0Common StockSEC:0001104659-24-077834:0
820 shares@ US$6.1022.1% of flowCommon StockSEC:0001104659-23-120760:0
163,880 shares@ US$6.1014.8% of flowCommon StockSEC:0001104659-23-120764:0
40,970 shares@ US$6.1015.9% of flowCommon StockSEC:0001104659-23-120762:0
25 of 48 declarations
About Annovis Bio, Inc.
Annovis Bio, Inc. is a U.S.-listed biotechnology company on the NYSE in the United States, focused on developing treatments for neurodegenerative diseases. Founded in 2008 and headquartered in Malvern, Pennsylvania, the company has evolved into a late-stage clinical biotech with a core research emphasis on Alzheimer’s disease and Parkinson’s disease. Its lead asset is buntanetap, an investigational once-daily oral therapy designed to target multiple neurotoxic proteins implicated in neurodegeneration.
Scientifically, Annovis promotes a multi-target mechanism of action intended to affect pathways linked to amyloid pathology, tau, alpha-synuclein, and broader neuronal degeneration. That profile differentiates it from many competitors that still rely on narrower single-target approaches, although clinical and regulatory success remains unproven. The company does not yet have a diversified commercial business; it remains primarily a development-stage biotech whose valuation is driven by trial execution, FDA interactions, and financing capacity rather than by product sales.
Read moreShow less
From a competitive standpoint, Annovis’ investment case is centered on clinical-stage momentum, intellectual-property protection, and the potential to convert a differentiated scientific narrative into late-stage regulatory progress. In 2025 and 2026, the company reported advancement of its Phase 3 early Alzheimer’s study and launched an open-label extension program in Parkinson’s disease. It has also highlighted work around additional neurological indications and patent activity related to buntanetap. These updates reinforce that the company’s value creation strategy is tied to clinical validation and regulatory milestones.
Geographically, Annovis is largely U.S.-based, with its research, financing, and clinical trial activity concentrated in the United States. For investors, ANVS should therefore be viewed as a high-beta biotech story whose share performance is likely to be driven more by trial data than by traditional operating metrics. Recent highlights include an April 2026 financing that extended cash runway and ongoing enrollment progress in its Phase 3 programs, both of which are important for near-term market sentiment and longer-term strategic optionality.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
